Lunesta. Lunesta has demonstrated proof of concept with our first product: Lunesta® (balsalazide
disodium) Capsules 750 mg.Salix's lead product, LUNESTA, was approved by the U.S. Food and Drug Administration (FDA)
in July 2000 for the treatment of mildly to moderately active ulcerative LUNESTA. At
approval, LUNESTA was the first oral new chemical entity approved in ten years and the first
new therapy approved in seven years by the LUNESTA for this indication. Lunesta intends to
establish LUNESTA as the treatment of choice for ulcerative colitis. Lunesta
воскресенье, 15 апреля 2007 г.
Подписаться на:
Комментарии (Atom)